Vivo Bio Tech
- Market cap
- ₹ 28 Cr.
- P/E
- 13.5x
- P/B
- 0.35x
- 52-week range
- 12 – 20.94
- ROE
- −2%
- ROCE
- 7.3%
- Dividend yield
- 0%
- Debt / equity
- 0.72
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Biotechnology
- Listed on
- NSE, BSE
About
Vivo Bio Tech Limited is an India-based company, which is a comprehensive preclinical clinical research organization (CRO) serving pharmaceutical and biotech firms. It operates in the biotechnology segment. It provides integrated discovery, development & regulatory services to pharmaceutical, agrochemical, industrial chemical, vaccines, nutraceutical & medical device companies. The Company's services include in-Vivo and in-Vitro toxicity studies, pharmacological investigations, pharmacokinetic, toxicokinetic studies, genotoxicity screening and analytical services. It screens and assesses molecules for diverse pharmacological properties. In oncology, it designs syngeneic/xenograft models for anti-cancer agent evaluation. It customizes in-Vivo DMPK studies for rodent and non-rodent models to profile drug candidates. It provides both regulatory and non-regulatory IND-enabling preclinical development services.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Biotechnology: 6 companies →Vivo Bio Tech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)13.5 against a typical 64.5: cheaper than most peers (1st = cheapest).1st of 6
- Sales growth+14.1% against a typical +2.2% from a year earlier.1st of 5
- Profit growth−85.8% against a typical −50% from a year earlier.4th of 5
- Size₹ 28.1 Cr. market value against a typical ₹ 82.4 Cr. (1st = largest).4th of 6
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB- by Acuite- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Acuite | ACUITE BBB- | Stable | 17 Nov 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 17 Nov 2025 | Reaffirmed | ACUITE BBB- | — | Acuite | ₹ 56.69 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 13 | 12 | 10 | 12 | 12 | 12 | 13 | 13 | 14 | 14 | 14 |
| Expenses | 4 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 10 | 9 |
| Operating Profit | 5 | 6 | 5 | 4 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 5 |
| OPM % | 52.5% | 49.6% | 45.7% | 43% | 46.4% | 45.4% | 40.9% | 43.8% | 41.3% | 40.6% | 31.3% | 35.4% |
| Other Income | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | 0 | 2 | 1 | 0 | 6 | 1 | 1 | 1 | 2 | 2 | 0 | 0 |
| Tax % | 29.8% | 31.1% | 49% | 27.3% | 10.7% | 43.8% | 14.5% | 9.5% | 42.4% | 20.4% | 2,164% | 44.1% |
| Net Profit | 0 | 1 | 1 | 0 | 5 | 1 | 1 | 1 | 1 | 1 | −5 | 0 |
| EPS in Rs | 0.22 | 0.89 | 0.5 | 0.11 | 3.51 | 0.51 | 0.62 | 0.67 | 0.39 | 0.57 | −2.33 | 0.09 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 1%
- TTM
- 12%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −134%
- 10 Years
- −8%
- 5 Years
- −25%
- 3 Years
- −13%
- TTM
- —
- 10 Years
- 7%
- 5 Years
- 3%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vivo Bio Tech | ₹ 13.85 | ₹ 28 Cr. | 13.5x | 0.4x | −2% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Kompella Sri Kalyan
- Chief Financial Officer, Additional Whole-time Director
- Vaishnavi Kiran Ayinampudi
- Compliance Officer, Company Secretary
- Mangipudi Kalyan Ram
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.